Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673657 | 0.98 | KDM4E (0.38) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL19749146 | 0.98 | KDM4E (0.38) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL18773530 | 0.98 | KDM4E (0.38) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL21106579 | 0.91 | CYP2C19 (0.37) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL20812075 | 0.90 | CYP2C19 (0.41) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL10092557 | 0.85 | KDM4E (0.42) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL22861953 | 0.84 | HTT (0.35) | KDM4ECYP2C19CYP1A2CYP2D6HTT | |
| SCHEMBL22930120 | 0.83 | KDM4E (0.44) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL22837632 | 0.83 | KDM4E (0.44) | KDM4ECYP2C19CYP1A2CYP2D6POLB | |
| SCHEMBL18908660 | 0.83 | KDM4E (0.44) | KDM4ECYP2C19CYP1A2CYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| US-9771355-B2 | Compositions and methods for the treatment of epilepsy and neurological disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2017-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KDM4E 524/4885CYP2C19 3646/4885CYP1A2 2507/4885 |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | KDM4E 4760/4885CYP2C19 496/4885CYP1A2 708/4885 |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KDM4E 524/4885CYP2C19 3646/4885CYP1A2 2507/4885 |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | KDM4E 3790/4885CYP2C19 129/4885CYP1A2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.